Blueberries Medical (BBM) AI Stock Analysis

Blueberries Medical

(CNQX:BBM)

Select Model

Rating:39Underperform

Price Target:CAD 0.01▼(-6.67% Downside)

Action:reiterated

Date:10/28/26

The exceptionally low overall score of 39 is heavily driven by Blueberries Medical's severe fundamental and financial distress. While the stock manages to hold just above its long-term moving averages, massive cash burn, shrinking revenues, nearly wiped-out equity, and an inability to generate a profit pose critical existential risks to the company. Without external financing, the company's prospects remain highly speculative.

Positive Factors

Improved Gross MarginThe substantial improvement in gross margin indicates better economics on the revenue the company does generate. If maintained, stronger gross profitability can provide more resources to cover operating costs and improve the eventual path toward sustainable earnings.

Negative Factors

Revenue ContractionFalling trailing revenue weakens the scale needed to absorb the company’s operating cost base and makes a durable recovery more difficult. The choppy multi-year sales trend also suggests that growth has not yet become dependable enough to support predictable operating leverage.

Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 4.47M
Dividend Yield: ―
Average Volume (3M): 61.33K
Price to Earnings (P/E): -7.1
Beta (1Y): -2.21
Revenue Growth: -36.67%
EPS Growth: 40.54%
Country: Canada
Employees: 51
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Blueberries Medical Business Overview & Revenue Model

Company Description

Headquartered in Bogotá, Colombia, Blueberries Medical Corp. operates within the medicinal cannabis industry. The company's activities encompass the entire process, from cultivating and developing to producing and supplying medical-grade cannabis and...

Blueberries Medical Financial Statement Overview

Summary

Scores at the absolute minimum due to severe operational distress. The company suffers from shrinking revenue, deeply negative net margins (-384%), near-total depletion of equity, and chronic cash burn. It relies entirely on external capital for survival.

Income Statement

12Very Negative

Balance Sheet

18Very Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	278.21K	312.29K	471.41K	288.27K	235.45K	138.75K
Gross Profit	102.20K	49.50K	164.52K	84.22K	-17.72K	-245.45K
EBITDA	-695.46K	-1.28M	-1.04M	-1.22M	-811.47K	-4.05M
Net Income	-1.07M	-1.67M	-1.15M	-1.64M	-1.47M	-5.15M
Balance Sheet
Total Assets	670.10K	679.62K	1.38M	2.42M	3.35M	3.59M
Cash, Cash Equivalents and Short-Term Investments	14.77K	26.39K	66.08K	818.16K	1.41M	1.34M
Total Debt	8,282	137.88K	11.44K	12.80K	1.34M	1.44M
Total Liabilities	641.44K	358.45K	545.61K	470.72K	1.89M	2.16M
Stockholders Equity	28.66K	321.17K	834.81K	1.95M	1.47M	1.43M
Cash Flow
Free Cash Flow	-607.78K	-1.24M	-796.85K	-1.35M	-1.47M	-1.73M
Operating Cash Flow	-607.78K	-1.24M	-796.85K	-1.33M	-1.47M	-1.68M
Investing Cash Flow	0	0	9,003	382.92K	101.94K	-48.77K
Financing Cash Flow	394.76K	1.18M	-1,947	539.10K	1.35M	2.77M

Blueberries Medical Technical Analysis

Technical Analysis SentimentPositive

Last Price0.01

Price Trends

50DMA0.01Positive

100DMA0.01Positive

200DMA0.01Positive

Market Momentum

MACD0.00Negative

RSI51.88Neutral

STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:BBM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:CDVA	42Neutral	CAD 2.75M	-1.04	43.99%	―	-6.27%	44.49%
TSE:BBM	39Underperform	CAD 7.43M	-7.14	-332.63%	―	-36.67%	40.54%

* Healthcare Sector Average

Performance Comparison

TSE:BBM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:BBM	Blueberries Medical	0.01	0.00	0.00%
TSE:BAMM	Body & Mind	0.03	0.00	0.00%
TSE:CDVA	CordovaCann Corp	0.03	-0.00	-16.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Blueberries Medical AI Stock Analysis